Vietnam Set To Produce 20 Million Doses Of Tamiflu Generic
This article was originally published in PharmAsia News
Executive SummaryVietnam has decided to produce its own generic of Roche's Tamiflu (oseltamivir) to use in fighting the spreading H1N1 flu virus, if necessary. The minister of health said the country has 880,000 doses of the drug already, but also has the ingredients to make 20 million doses as needed. The Drug Administration of Vietnam is holding back 10 million tablets that have not been completed and has asked local drug makers to stock Tamiflu and be prepared to order imports of the drug if local demand rises. (Click here for more
You may also be interested in...
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.
Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.